Highlights from the Critical Care Canada Forum 2009 - 25 to 28 October 2009, Toronto, Ontario, Canada by McCullagh, Iain J & Scales, Damon C
Th  e Critical Care Canada Forum was held in Toronto, 
Canada from 25 to 28 October 2009 [1]. Th  e  conference, 
which focuses on the care of critically ill patients 
wherever the patients are located, was attended by 879 
delegates and featured 197 separate presentations, 
includ  ing several as yet unpublished trials. Th   e hot topic 
this year was planning for the impact of a worldwide 
outbreak of H1N1 inﬂ  uenza on critical care systems, but 
the conference also covered a broad range of critical care 
interventions including mechanical ventilation, sedation 
and analgesia, renal replacement therapy, and extra-
corporeal membrane oxygenation. Herein we summarize 
just a few of the many exciting clinical trials and plenary 
topics presented at the conference.
H1N1 pandemic
Th  e Critical Care Canada Forum 2009 featured several 
presentations describing the outcomes of critically ill 
patients with H1N1 virus infection from Australia, Mexico, 
and Canada.
Dr Jamie Cooper (Melbourne, Australia), speaking on 
behalf of the Australia–New Zealand Intensive Care 
Inﬂ  uenza Investigators [2], described outcomes of 722 
patients with conﬁ  rmed H1N1 virus infection that were 
admitted to 187 intensive care units. Of these patients, 
most (92%) were younger than age 65, and large 
proportions were pregnant (9.1%) or had a body mass 
index >35 (28.6%). Th  e overall mortality rate (as of 
September 2009) was 14.3% (95% conﬁ  dence interval = 
11.7 to 16.9%). Nitric oxide, inhaled prostacyclin, and 
prone positioning were used frequently to treat refractory 
hypoxemia. Outcomes of 68 patients from 15 centres 
who were treated with extracorporeal membrane 
oxygenation were also described [3]. Illness severity was 
predictably very high in this group, and the overall hospital 
mortality was 23% with most deaths due to haemorrhage.
Dr Anand Kumar (Winnipeg, Canada) and Dr Rob 
Fowler (Toronto, Canada) presented data from the 
Canadian Experience [4]. Severe illness due to H1N1 
infection (conﬁ   rmed or probable) occurred in 168 
patients during a 4-month period. Similar to the Australian–
New Zealand experience, the cohort was young (mean 
age 32 years), and females, children, and the obese were 
disproportionally aﬀ   ected by severe illness requiring 
critical care. Th   e overall mortality at 90 days was 17.3% 
(95% conﬁ  dence interval = 12.0 to 24%). Notably, one-
quarter of cases involved First Nations Canadians, Inuit, 
Métis, or aboriginals. Rescue therapies to treat refractory 
hypoxemia, including nitric oxide and high-frequency 
oscillation, were also commonly required in this group.
Dr Guillermo Dominguez (Mexico City, Mexico) next 
presented outcomes of 58 critically ill patients with H1N1 
infection in Mexico [5]. Th   is cohort was one of the ﬁ  rst to 
be aﬀ  ected by the pandemic, and mortality at 60 days was 
high (41.4%, 95% conﬁ  dence interval = 28.9 to 55.0%).
Together, these presentations highlighted the potential 
importance of early treatment with neuraminidase inhibi-
tors. Following the session, 240 of the Critical Care Canada 
Forum delegates received the H1N1 vaccine through a 
team from the Toronto Public Health Department.
Renal replacement therapy
Dr Jamie Cooper (Melbourne, Australia) also presented 
the recently published RENAL study (Randomized 
Evaluation of Normal vs. Augmented Level of renal 
replace  ment therapy in ICU) [6] on behalf of the 
Australian and New Zealand Intensive Care Society 
Clinical Trials Group and the George Institute for Inter-
national Health. Th   is study randomized 1,508 patients to 
receive either lower intensity (25 ml/kg body weight/
hour) or higher intensity (40 ml/kg body weight/hour) 
post-dilution continuous venovenous haemodiaﬁ  ltration. 
At 90 days, mortality in both groups was the same 
(44.7%) (odds ratio = 1.00, 95% conﬁ  dence interval = 0.81 
to 1.23; P = 0.99). Higher rates of hypophosphataemia  © 2010 BioMed Central Ltd
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© 2010 BioMed Central Ltdwere observed in the higher intensity group. Dr Cooper 
concluded that the results of this study and the recently 
published Veterans Aﬀ  airs/National Institutes of Health 
Acute Renal Failure Trial Network study [7], which 
produced similar ﬁ  ndings, suggest that higher intensity 
renal replacement therapy does not lead to lower 
mortality for critically ill patients.
Intensive care unit follow-up programmes
Dr Brian Cuthbertson (Toronto, Canada) presented the 
PRaCTICaL study, a UK multicentre randomized controlled 
trial of intensive nurse-led intensive care unit follow-up 
programmes versus standard care [8]. Th  e intervention 
included clinic visits and a self-directed physical rehabili-
tation programme. In total, 286 patients were included 
and 192 completed 1-year follow-up. Th  ere was no 
evidence of a diﬀ  erence in the main outcome measure – 
health-related quality of life measured using the Short 
Form 36 questionnaire at 12 months. During the 
discussion follow  ing the presentation, it was suggested 
that future studies should consider focusing on diﬀ  erently 
timed or diﬀ  er  ently structured programmes to improve 
long-term out  comes of patients following intensive care 
unit discharge.
Industry and medicine
Dr Tom Stossel (Boston, USA) and Dr Allan Detsky 
(Toronto, Canada) engaged in an exciting debate about 
the pros and cons of allowing for-proﬁ  t companies to 
become involved in healthcare research, medical educa-
tion, and clinical practice. Dr Stossel reminded delegates 
of the large number of new products and innovations 
that were introduced during the past 30 years that would 
probably not have been developed without signiﬁ  cant 
investment from industry. He also discussed the extent to 
which US government legislation now restricts the 
activities of industry in that country. In his response, Dr 
Detsky reasoned that there should always be a clear 
separation between funding for research and funding for 
marketing and promotion. He also argued that groups 
tasked with developing clinical guidelines should be 
discouraged from accepting funding from industry to 
reduce the potential for a conﬂ  ict of interest.
Conclusion
Th   e above is just a small selection of the many fascinating 
clinical and basic science topics that were presented at 
this year’s meeting, including rehabilitation and early 
mobilization after critical care, acute respiratory distress 
syndrome, cardiology problems in critical care, and 
transfusion medicine. Planning for next year’s meeting is 
already under  way and it promises to maintain the same 
very high standard of critical care education. Save the 
date: 6 to 10 November 2010.
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